Cure8 research brief
Automated, quantitative analysis of pathology slides could reduce variability in histological scoring and help track histological healing — a growing therapeutic target in ulcerative colitis.
Clinicians who use histology for UC assessment, pathology researchers, and computational researchers developing AI tools for IBD.
The authors retrospectively collected pathology slides from 167 UC patients and extracted quantitative image features including gland geometry, texture (GLCM), and grayscale histograms. A U-Net segmented gland structures and feature selection used LASSO.
Several machine-learning classifiers were compared; a support-vector machine (SVM) was selected and reported strong performance on an internal test set (AUC reported in the paper). The model is presented as a complementary auxiliary tool for binary histological stratification (mild vs. moderate-to-severe) rather than a standalone diagnostic.
The work is internally validated with cross-validation and an independent test split, and the authors provide supplementary material on segmentation and features.
This is a retrospective single/internal validation study using slides from two centers; results reflect internal performance and will need external validation and prospective testing before clinical use. The article is an open-access peer-reviewed journal publication; supplementary files describe methods and segmentation details.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Fujian Provincial Health Technology Project, award No.2024GGA030; Joint Funds for the Innovation of Science and Technology, award No.2024Y9194
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
Improving accuracy of IBD case identification in EMRs can make research and registries more reliable, reduce misclassification, and help ensure studies and quality programs use the right patient groups.
The work highlights macrophage metabolic programs and specific genes that may help classify UC molecular subtypes and suggest candidate biomarkers or therapeutic targets related to macrophage-driven inflammation.
